Genetic lesions in chronic lymphocytic leukemia: What's ready for prime time use?

Haematologica

Volumn 95, Issue 1, 2010, Pages 12-15

  Moreno, Carol ^a   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; PROTEIN IVGH; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CANCER RESISTANCE; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; PROGNOSIS;

ANIMALS; GENE THERAPY; GENETIC MARKERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TIME FACTORS;

EID: 73949101232     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016873     Document Type: Editorial

References (31)

1. Kienle D, Benner A, Läufle C, Winkler D, Schneider C, Bühler A, et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica. 2010;95(1):102-9.
2. Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica. 2010;95(1):110-8.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
4. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7.
5. Tobin G, Thunberg U, Johnson A, Thorn I, Sodeberg O, Hultdin M, et al. Somatically mutated IgV(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99(6):2262-4.
6. Thorselius M, Kröber A, Murray F, Thunberg U, Tobin G, Bühler A, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107(7):2889-94.
7. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-75.
8. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
9. Müller-Hermelink KH, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Eds. Swerdlow SH, Campo E, Harris NL et al. WHO Press. 2008; pp:180-4.
10. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger LL, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
11. Stilgenbauer S, Bullinger L, Benner A, Benner A, Leupolt E, Winkler D, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia. 1999:13(9):1331-41.
12. Neilson JR, Auer R, White D, Bienz N, Waters JJ, Whittaker JA, et al. Deletions at 11q identify a subgroup of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia. 1997;11(11):1229-32.
13. Zenz T, Meterns D, Döhner H, Stingelbauer S. Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. Leuk Lymphoma. 2008; 49(5):864-73.
14. Catovsky D, Richards S, Oscier D, Dyer MJS, Bezares RF, Pettit AR, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomized controlled trial. Lancet 2007;370(9583):230-9.
15. Tsimberidou AM, Tam, C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):373-80.
16. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107(2):742-51.
17. Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol. 2008;142(4): 529-37.
18. Stilgenbauer S, Sander S, Bullinger L, Wildenberger K, Bentz M, Döhner K, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92(9):1242-5.
19. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634-41.
20. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-9.
21. Rossi D, Cerri M, Deambrogi C Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009 15(3):995-1004.
22. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009;113(14):3168-71.
23. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood. 2009;114(5):957-64.
24. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(32):11755-60.
25. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-801.
26. Visone R, Rassenti LZ, Veronesse A, Taccioli C, Costinean S, Aguda BD, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009; 114(18):3872-9.
27. Gunn SR, Hibbard MK, Ismail SH, Lowery-Nordberg M, Mellink CH, Bahler DW, et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia. 2009; 23(5):1011-7.
28. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 2009; 114(15); 3255-65.
29. Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res. 2009;15(22):6947-55.
30. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458(7239):719-24.
31. Hirschhorn JN. Genomewide association studies - illuminating biologic pathways. N Engl J Med. 2009;360(17):1699-701.